SA
CHE icon

Shilanski & Associates’s Chemed CHE Stock Holding History

Shilanski & Associates’s Portfolio CHE Stock Details CHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,510
Closed -$725K – 99
2020
Q3 		$725K Buy
1,510
+3
+0.2% +$1.47K 0.49% 58
2020
Q2 		$680K Buy
+1,507
New +$673K 0.5% 57

Other funds holding CHE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Shilanski & Associates's CHE Position: Q4 2020 in Review

Shilanski & Associates sold out of Chemed (CHE) in Q4 2020, closing a stake of 1,510 shares — an estimated $725K sold.

Shilanski & Associates first reported a position in CHE in Q2 2020 and held it in 2 quarters. The position peaked at $725K in Q3 2020. 442 funds tracked by Wall St. Rank hold CHE as of Q4 2020.

  • Shilanski & Associates reported no remaining Chemed position as of Q4 2020 after selling out during the quarter.
  • Shilanski & Associates sold 1,510 Chemed shares in Q4 2020, an estimated $725K.
  • Shilanski & Associates first reported a position in Chemed in Q2 2020 and held it in 2 quarters.
  • Shilanski & Associates's Chemed position peaked at $725K in Q3 2020.
  • 442 funds tracked by Wall St. Rank held Chemed as of Q4 2020.

Based on Shilanski & Associates's 13F filing for Q4 2020, filed 3 Feb 2021.